Stem sel
Financials
Estimates*
EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|
Revenues | - | - | <1m | <1m | <1m | <1m | <1m |
% growth | - | - | - | (91 %) | 300 % | - | - |
EBITDA | <1m | (<1m) | (<1m) | (<1m) | (<1m) | - | - |
% EBITDA margin | - | - | (750 %) | (6776 %) | (3326 %) | - | - |
Profit | <1m | (<1m) | (<1m) | (<1m) | (<1m) | - | - |
% profit margin | - | - | (1159 %) | (10890 %) | (4157 %) | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Spinout | ||
N/A | €109k | Angel | |
€50.0k | Grant | ||
N/A | €190k | Debt | |
N/A | €300k | Seed | |
N/A | €230k | Early VC | |
N/A | €145k | Debt | |
N/A | €330k | Seed | |
N/A | €192k | Seed | |
N/A | N/A | - | |
Total Funding | CAD1.8m |
Related Content
Recent News about Stem sel
EditStem Sel s.r.l. is an innovative biotechnology company based in Bologna, Italy, specializing in the development of advanced stem cell selection technologies. The company serves clients in the medical and research sectors, focusing on improving the efficiency and precision of cell therapy applications. Operating within the biotechnology market, Stem Sel's core product is a patented technology that enables the selective isolation of stem cells from various sources, which is crucial for regenerative medicine and research purposes.
Stem Sel's business model revolves around the sale and licensing of its proprietary technology to medical institutions, research laboratories, and biotech companies. Revenue is generated through direct sales, licensing agreements, and collaborative research projects. The company has garnered recognition through various awards, highlighting its innovative approach and contribution to the field of biotechnology.
Keywords: stem cell selection, biotechnology, regenerative medicine, cell therapy, medical research, patented technology, innovation, licensing, collaborative research, Italy.